ArticleCurrent oncology (Toronto, Ont.)2023

Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec's University Teaching Hospitals (DALP-First Study).

Ghislain Bérard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.